Weill Medical College of Cornell University
The goal of this clinical trial is to learn if FHD-286 in combination with mosunetuzumab is safe and tolerable for treating adults with previously treated relapsed/refractory follicular lymphoma. It will also evaluate how well the combination works and how it affects cancer-related molecular and immune markers.The main questions it aims to answer are: * What is the maximum tolerated dose of FHD-286 when given in combination with mosunetuzumab? * Is the combination of FHD-286 and mosunetuzumab safe and tolerable? * How many participants have a response to treatment, and how long does the treatment control the disease? * How does treatment affect circulating tumor DNA (ctDNA), immune responses, and molecular markers, including BAF complex mutational status? Researchers will evaluate FHD-286 in combination with mosunetuzumab in participants with relapsed or refractory follicular lymphoma to assess safety, tolerability, and preliminary anti-tumor activity.
Follicular lymphoma (FL) which has relapsed following initial therapy is difficult to treat and carries significant associated morbidity. Cellular therapy, which includes chimeric antigen receptor (CAR) T cell therapy and bispecific antibody treatment, has become a cornerstone of treatment for relapsed FL, though most patients eventually experience disease relapse and durations of response (DOR) are often limited. Relapsed FL is enriched for mutations within subunits of the BAF nucleosome remodeling complex, which confer lymphoma B cells with a less differentiated, proliferative state. Inhibit…
Inclusion Criteria: * Histologically confirmed diagnosis of FL * FL meeting criteria for initiation of systemic therapy per treating investigator and institutional standards * Eligible for SOC mosunetuzumab, which is currently FDA approved in FL after at least two prior lines of therapy * Age ≥ 18 years * ECOG performance status ≤ 2 (Appendix A) * Required initial laboratory parameters:, Hemoglobin ≥ 7 g/dL; transfusions permissible at treating physician discretion. Absolute neutrophil count (ANC) ≥ 1000 cells/mm3. Platelet count ≥ 75,000 cells/mm3. Calculated creatinine clearance ≥ 45 ml/min…
will be administered per SOC procedures
will be administered in 2.5mg, 5mg, 7.5mg, or 10mg doses, depending on dose level, by oral tablet
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.